NeurAxis Reports Impressive Fourth Quarter Financial Outcomes
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS) has shared notable results for the fourth quarter of 2024. This medical technology firm focuses on pioneering neuromodulation solutions for those grappling with chronic ailments in both pediatric and adult demographics. The Company has seen remarkable growth, attributed to its commitment to advancing healthcare solutions.
Strong Growth in 4Q2024
During the fourth quarter of 2024, NeurAxis achieved revenues of $761 thousand, marking a 43% increase compared to the previous year’s fourth quarter revenue of $531 thousand. This growth was primarily driven by the company’s robust initiatives in patient care and expanding insurance reimbursements.
Key Financial Highlights
The Company demonstrated significant improvements in its financial metrics. There was a notable 10% reduction in the operating loss for the quarter, reflecting operational efficiency and effective cost management strategies. NeurAxis concluded the year with a solid cash balance of $3.7 million, paving the way for future investments and innovations.
Operational Advancements and Innovations
NeurAxis has continuously worked to escalate its operational reach. Its initiatives have expanded the number of covered lives to approximately 51 million, a leap from 4 million the previous year. This is a testament to the Company’s effective negotiation and partnership strategies within the healthcare sector.
New Regulatory Approvals
In a remarkable milestone, NeurAxis secured a new CPT Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures that will become effective in the near future. Additionally, the FDA granted clearance for the enhancement of the IB-Stim label, broadening treatment options to include an older patient demographic as well as allowing for increased devices per patient.
Company Leadership Insights
Brian Carrico, the Chief Executive Officer, shared insight into the Company’s remarkable progress during this transformative year. He emphasized the expansion of insurance coverage and the positive trajectory in revenues, highlighting that over 1,000 pediatric patients have been treated with the innovative IB-Stim therapy. Carrico noted that this therapy has just begun to gain traction and that the Company is poised for continued growth.
Positive Policy Coverage and Future Expectations
With favorable policy coverage for approximately 51 million lives already in effect, NeurAxis is actively working with various payers to implement new insurance policies that reflect its advancements in pediatric healthcare solutions. Expectations for future growth remain high with the anticipated guidelines from academic societies set to augment insurance policy coverage significantly.
Overall Financial Performance for Fiscal Year 2024
For the whole of 2024, NeurAxis reported revenues of $2.7 million, which is a 9% increase from $2.5 million in 2023. Despite the progress, the ongoing support and development of the Company’s financial assistance program are crucial as they help to bridge the gap for uninsured patients, which has positively influenced unit sales growth.
Stability in Gross Margin
The Company's gross margin stood at an impressive 86.4% for the fourth quarter, consistent with the previous year’s performance. Ongoing efforts to grow their higher-margin insurance reimbursement program have contributed significantly to this stability!
Outlook for the Future
The outlook for NeurAxis remains positive, with initiatives in place to apply for additional FDA clearances and potentially doubling their total addressable market in pediatric care in 2025. As the company aims for broad-scale growth, management’s clear vision and ongoing strategic investments are aimed at achieving both growth and profitability milestones.
Conclusion
NeurAxis, Inc. stands at a pivotal point as they continue to innovate in the realm of neuromodulation therapy. With strong financial results, operational improvements, and an upbeat forecast, the company is well-positioned for ongoing success in enhancing the health and well-being of those affected by chronic conditions.
Frequently Asked Questions
1. What were the key financial highlights for NeurAxis in 4Q24?
NeurAxis reported a 43% increase in revenues, reaching $761 thousand, and a 10% improvement in operating loss.
2. How did NeurAxis expand its coverage?
The company expanded its covered lives significantly, reaching approximately 51 million compared to 4 million the previous year.
3. What new regulatory approvals did NeurAxis receive?
NeurAxis received CPT Category I code for PENFS and increased FDA clearances for its IB-Stim label and rectal expulsion device.
4. What is the future outlook for NeurAxis?
With robust growth prospects and pending FDA clearances, NeurAxis is expected to further expand its market presence and improve industry standards.
5. What is the significance of NeurAxis's recent financial performance?
The strong revenue growth reflects successful operational and strategic efforts to enhance product offerings and expand insurance coverage.
